Belite Bio, Inc (BLTE): Total Liabilities
$10.07M
As of 2025-12-31
+53.7%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.07M | +59.6% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $6.31M | +49.9% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $4.21M | +51.9% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $2.77M | +69.5% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $1.64M | n/a | 2023-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Belite Bio, Inc (BLTE) | 2025-12-31 | $10.07M | +59.6% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $62.55M | -31.0% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| MannKind Corp (MNKD) | 2025-12-31 | $843.20M | +78.4% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $262.35M | -13.0% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $67.05M | +26.1% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $153.75M | +7.8% |
Compare BLTE, SYRE, MRVI, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗